Kyverna Therapeutics, Inc. 8-K

What Happened
Kyverna Therapeutics, Inc. (KYTX) filed a Current Report on Form 8-K on April 20, 2026 to disclose a press release announcing positive longer-term follow-up data from the Phase 2 portion of its KYSA-6 Phase 2/3 registrational trial of mivocabtagene autoleucel (miv-cel, KYV-101) in patients with generalized myasthenia gravis (gMG). The company said it will review the results on a conference call scheduled for April 22, 2026 at 7:00 a.m. Eastern Time. The press release is furnished as Exhibit 99.1 to the 8-K.

Key Details

• Filing date: April 20, 2026 (Form 8-K, Item 7.01 Regulation FD Disclosure).
• Study: Positive longer-term follow-up from the Phase 2 portion of the KYSA-6 Phase 2/3 registrational trial for miv-cel (KYV-101) in gMG.
• Event: Conference call to review results on April 22, 2026 at 7:00 a.m. ET.
• Exhibit: Press release dated April 20, 2026 furnished as Exhibit 99.1 to the 8-K.

Why It Matters
Positive longer-term Phase 2 data is a material clinical update for Kyverna’s registrational program for miv-cel in gMG and may influence investor perception of the company’s clinical progress. The 8-K does not include efficacy or safety figures in its text; investors should review the press release (Exhibit 99.1) and listen to the April 22 conference call for detailed data and management commentary.